Skip to main content
Download PDF

Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease

Arthritis Research & Therapy volume 21, Article number: 69 (2019) Cite this article

The Original Article was published on 13 February 2019

Correction to: Arthritis Res Ther

https://doi.org/10.1186/s13075-019-1843-9

Following publication of the original article [1], the authors reported an error in the spelling of Lorenzo Dagna’s name. The authors apologise for the error.

Incorrect spelling:

Loreno Dagna

Correct spelling:

Lorenzo Dagna

The original article [1] has been updated.

Reference

  1. Cavalli, et al. Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease. Arthritis Res Ther. 2019;21:54 https://doi.org/10.1186/s13075-019-1843-9.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Unit of Immunology, Rheumatology, Allergy and Rare Diseases, IRCCS San Raffaele Hospital, Vita-Salute San Raffaele University, Via Olgettina 60, 20132, Milan, Italy

    Giulio Cavalli, Alessandro Tomelleri, Giacomo De Luca, Corrado Campochiaro, Elena Baldissera & Lorenzo Dagna

  2. Vita-Salute San Raffaele University, Milan, Italy

    Giulio Cavalli, Alessandro Tomelleri, Giacomo De Luca & Lorenzo Dagna

  3. Department of Medicine, Radboud University Medical Center, Nijmegen, The Netherlands

    Giulio Cavalli & Charles A. Dinarello

  4. Department of Medicine, University of Colorado Denver, Aurora, CO, 80045, USA

    Charles A. Dinarello

Authors
  1. Giulio Cavalli
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alessandro Tomelleri
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Giacomo De Luca
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Corrado Campochiaro
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Charles A. Dinarello
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Elena Baldissera
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lorenzo Dagna
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giulio Cavalli.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cavalli, G., Tomelleri, A., De Luca, G. et al. Correction to: Efficacy of canakinumab as first-line biologic agent in adult-onset Still’s disease. Arthritis Res Ther 21, 69 (2019). https://doi.org/10.1186/s13075-019-1850-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s13075-019-1850-x

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us